Disease-modifying therapies in systemic lupus erythematosus for extrarenal manifestations

Author:

Askanase Anca DORCID,Furie Richard A,Dall'Era Maria,Bomback Andrew S,Schwarting Andreas,Zhao Ming-Hui,Bruce Ian NORCID,Khamashta Munther,Rubin Bernie,Carroll Angela,Daniels Mark,Levy Roger AbraminoORCID,van Vollenhoven RonaldORCID,Urowitz Murray BORCID

Abstract

Our 2022 published working definition of disease modification in systemic lupus erythematosus (SLE) was ‘minimising disease activity with the fewest treatment-associated toxicities and slowing or preventing organ damage progression’. The objective of this review was to classify current SLE treatments according to the proposed non-renal disease modification criteria excluding toxicities. Based on a review of select clinical trial (n=32) and observational study (n=54) publications for 14 SLE medications across different therapeutic classes, and the authors’ clinical experience, we evaluated disease modification potential as per the proposed framework at three time points. Specific criteria used to determine disease modification potential included a drug’s capacity to reduce: (1) non-renal disease activity, (2) severe flares, (3) use of steroids/immunosuppressants and (4) organ damage accrual. Criteria 1–3 were assessed at 1 year and 2–5 years and, when positive, were considered evidence for disease modification potential; criterion 4 was used to confirm disease modification at >5 years. Each treatment received one of four mutually exclusive designations at each time point: (a) criterion met, (b) indications of criterion met despite insufficient evidence in the literature, (c) inconclusive and (d) no available supportive data. This review excludes an assessment of potential toxicities. Eight of the 14 SLE treatments met ≥1 disease modification criteria up to year 5. Hydroxychloroquine improved overall survival at >5 years, suggesting long-term disease modification, but no data on specific organ systems were reported. Belimumab was the only treatment to meet all criteria. Belimumab and hydroxychloroquine met disease modification definitions across three time points. Evidence for other SLE therapies was incomplete, particularly at >5 years. Future studies are warranted for other treatments to meet the disease modification criteria. We discuss challenges to classification and possible updates to our published criteria.

Funder

GSK

Publisher

BMJ

Reference87 articles.

1. Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort;Urowitz;Arthritis Care & Research,2012

2. Prevalence, predictors, and Prognostic benefits of remission achievement in patients with systemic lupus erythematosus: A systematic review;Yang;Arthritis Care & Research,2022

3. Diagnosis and Management of Rheumatoid Arthritis

4. American college of rheumatology . ACR glossary: disease modifying Antirheumatic drugs (Dmards). n.d. Available: https://www.rheumatology.org/Learning-Center/Glossary/ID/453

5. European Medicines Agency . Guideline on the clinical investigation of medicines for the treatment of Alzheimer’s disease. n.d. Available: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicines-treatment-alzheimers-disease-revision-2_en.pdf

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3